Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors: A Phase I, Open-label, Dose-escalation Study
Phase of Trial: Phase I
Latest Information Update: 19 Apr 2017
At a glance
- Drugs BPI 9016 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Betta Pharmaceuticals Co Ltd
- 10 Jun 2017 Biomarkers information updated
- 14 Apr 2017 Planned End Date changed from 1 May 2017 to 1 Dec 2017.
- 14 Apr 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Aug 2017.